Brian K. Kaspar Sells 15,000 Shares of AveXis, Inc. (AVXS) Stock
AveXis, Inc. (NASDAQ:AVXS) insider Brian K. Kaspar sold 15,000 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $94.73, for a total value of $1,420,950.00. Following the sale, the insider now directly owns 1,826,502 shares in the company, valued at approximately $173,024,534.46. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
AveXis, Inc. (NASDAQ:AVXS) opened at $91.97 on Thursday. AveXis, Inc. has a 12 month low of $44.68 and a 12 month high of $108.27.
AveXis (NASDAQ:AVXS) last released its quarterly earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.04). During the same period in the previous year, the firm posted ($0.87) earnings per share. sell-side analysts predict that AveXis, Inc. will post -6.23 EPS for the current year.
A number of large investors have recently added to or reduced their stakes in AVXS. Strs Ohio purchased a new position in AveXis during the 3rd quarter worth approximately $116,000. Botty Investors LLC purchased a new position in shares of AveXis in the 2nd quarter valued at approximately $123,000. Ameritas Investment Partners Inc. grew its stake in shares of AveXis by 331.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock valued at $174,000 after purchasing an additional 1,622 shares during the last quarter. Cubist Systematic Strategies LLC grew its stake in shares of AveXis by 688.6% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock valued at $175,000 after purchasing an additional 1,577 shares during the last quarter. Finally, Teacher Retirement System of Texas purchased a new position in shares of AveXis in the 3rd quarter valued at approximately $200,000. Hedge funds and other institutional investors own 92.88% of the company’s stock.
Several equities research analysts have recently weighed in on the company. ValuEngine lowered AveXis from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Bank of America cut their target price on AveXis from $115.00 to $112.00 and set a “buy” rating on the stock in a research report on Friday, November 10th. Royal Bank Of Canada raised their target price on AveXis from $92.00 to $97.00 and gave the stock a “sector perform” rating in a research report on Friday, November 10th. Chardan Capital reissued a “buy” rating on shares of AveXis in a research report on Thursday, November 2nd. Finally, Zacks Investment Research lowered AveXis from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and thirteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $110.67.
TRADEMARK VIOLATION NOTICE: “Brian K. Kaspar Sells 15,000 Shares of AveXis, Inc. (AVXS) Stock” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/12/07/brian-k-kaspar-sells-15000-shares-of-avexis-inc-avxs-stock.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.